MENUNews Archive
Date: 12/11/2024
Many cancer patients struggle with their conditions by having negative thoughts, behaviors and emotions.
Date: 12/11/2024
Researchers say the technology could one day be applied to other cancers
Date: 12/09/2024
A research partnership between Michigan Medicine and Gift of Life Michigan has revealed a new pathway to understanding the progression of pancreatic cancer.
Date: 12/09/2024
Novel finding suggests a possible target for improving response to immune-based cancer treatments
Date: 12/05/2024
The University of Michigan Rogel Cancer Center has named Kyle Cuneo, M.D., its new associate director for clinical research. In addition, a new position of assistant director for clinical research will be filled by John Magenau, M.D. Cuneo and Magenau will collaborate with leaders across Michigan Medicine and the University of Michigan to establish processes and infrastructure in support of cancer-focused clinical research.
Date: 12/04/2024
A study from researchers at the University of Michigan and the University of California San Diego has shed light on a previously poorly understood aspect of breast cancer recurrence: how cancer cells survive in bone marrow despite targeted therapies. The paper, “Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels,” appears in the Journal of Clinical Investigation.
Date: 11/25/2024
The 66th American Society of Hematology 2024 annual meeting, will be Dec. 7-10 at the San Diego Convention Center in San Diego, California, and online. University of Michigan faculty and trainees will present or moderate more than two dozen sessions and posters.
Date: 11/25/2024
Clinical trials testing cancer immunotherapies significantly under-represented Black patients. So while these treatments have resulted in dramatically improved outcomes for some patients, researchers from the University of Michigan Rogel Cancer Center wanted to understand whether that success holds true for patients who are Black.
Date: 11/20/2024
Drugs that suppress UBA1 could make immune checkpoint blocking immunotherapy effective for patients with prostate cancer and other “cold” tumors
Date: 10/30/2024
The gift will create the Rogel and Blondy Center for Pancreatic Cancer in honor of Max Rogel and Allen Blondy, Richard and Susan Rogel’s fathers, both of whom died from cancer. It will provide support for clinical care and translational research, playing to the strengths of the Rogel Cancer Center’s current robust team of 60 doctors and scientists from 10 departments already working in this area.